Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: Analysis of clinical trials of human rotavirus vaccine

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 2, 2014, Pages 505-511

  Cheuvart, Brigitte ^a   Neuzil, Kathleen M ^b   Steele, A Duncan ^c,h   Cunliffe, Nigel ^d   Madhi, Shabir A ^e   Karkada, Naveen ^f   Han, Htay Htay ^g   Vinals, Carla ^a  

^a GSK   (Belgium)

^b PATH   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e NATIONAL RESEARCH FOUNDATION   (South Africa)

^f GlaxoSmithKline Pharmaceuticals Ltd   (India)

^g GLAXOSMITHKLINE   (United States)

^h BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

Correlate of efficacy; Gastroenteritis; Meta analysis; Rotavirus; RV1; Vaccine

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; PLACEBO; ROTAVIRUS VACCINE; BIOLOGICAL MARKER; IMMUNOGLOBULIN A; VIRUS ANTIBODY;

ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; META ANALYSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTAVIRUS INFECTION; VACCINATION; VIRAL GASTROENTERITIS; BLOOD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROENTERITIS; IMMUNOLOGY; INCIDENCE; INFANT; MALE; RANDOMIZED CONTROLLED TRIAL; ROTAVIRUS; ROTAVIRUS INFECTIONS; SERUM; STATISTICS;

ANTIBODIES, VIRAL; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROENTERITIS; HUMANS; IMMUNOGLOBULIN A; INCIDENCE; INFANT; MALE; ROTAVIRUS; ROTAVIRUS INFECTIONS; SERUM; STATISTICS AS TOPIC;

EID: 84896968431     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27097     Document Type: Article

References (34)

1. Velázquez FR, Matson DO, Guerrero ML, Shults J, Calva JJ, Morrow AL, Glass RI, Pickering LK, Ruiz-Palacios GM. Serum antibody as a marker of protection against natural rotavirus infection and disease. J Infect Dis 2000; 182:1602-9; PMID:11069230; http://dx.doi.org/10.1086/317619
2. Chiba S, Yokoyama T, Nakata S, Morita Y, Urasawa T, Taniguchi K, Urasawa S, Nakao T. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986; 2:417-21; PMID:2874413; http://dx.doi.org/10. 1016/ S0140-6736(86)92133-1 (Pubitemid 16039239)
3. Hjelt K, Grauballe PC, Paerregaard A, Nielsen OH, Krasilnikoff PA. Protective effect of preexisting rotavirus-specific immunoglobulin A against naturally acquired rotavirus infection in children. J Med Virol 1987; 21:39-47; PMID:3025356; http:// dx.doi.org/10.1002/jmv.1890210106 (Pubitemid 17215493)
4. Matson DO. Protective immunity against group A rotavirus infection and illness in infants. Arch Virol Suppl 1996; 12:129-39; PMID:9015110 (Pubitemid 126446221)
5. O'Ryan ML, Matson DO, Estes MK, Pickering LK. Anti-rotavirus G type-specific and isotypespecific antibodies in children with natural rotavirus infections. J Infect Dis 1994; 169:504-11; PMID:8158022; http://dx.doi.org/10. 1093/ infdis/169.3.504 (Pubitemid 24062990)
6. Wood D; WHO Informal Consultative Group. WHO informal consultation on quality, safety and efficacy specifications for live attenuated rotavirus vaccines Mexico City, Mexico, 8-9 February 2005. Vaccine 2005; 23:5478-87; PMID:16129525; http:// dx.doi.org/10.1016/j.vaccine.2005.07.035 (Pubitemid 41608596)
7. Gladstone BP, Ramani S, Mukhopadhya I, Muliyil J, Sarkar R, Rehman AM, Jaffar S, Gomara MI, Gray JJ, Brown DW, et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011; 365:337-46; PMID:21793745; http:// dx.doi.org/10.1056/NEJMoa1006261
8. Angel J, Franco MA, Greenberg HB. Rotavirus immune responses and correlates of protection. Curr Opin Virol 2012; 2:419-25; PMID:22677178; http://dx.doi.org/10.1016/j.coviro.2012.05.003
9. Jiang B, Gentsch JR, Glass RI. The role of serum antibodies in the protection against rotavirus disease: an overview. Clin Infect Dis 2002; 34:1351-61; PMID:11981731; http://dx.doi.org/10.1086/340103 (Pubitemid 34507945)
10. Patel M, Glass RI, Jiang B, Santosham M, Lopman B, Parashar U. A systematic review of anti-rotavirus serum IgA antibody titer as a potential correlate of rotavirus vaccine efficacy. J Infect Dis 2013; 208:284-94; PMID:23596320; http://dx.doi.org/10.1093/ infdis/jit166
11. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine 2006; 24:2718-31; PMID:16446014; http://dx.doi. org/10.1016/j.vaccine.2005.12.048
12. Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, et al.; Human Rotavirus Vaccine Study Group. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006; 354:11-22; PMID:16394298; http://dx.doi.org/10.1056/ NEJMoa052434 (Pubitemid 43048947)
13. Araujo EC, Clemens SA, Oliveira CS, Justino MC, Rubio P, Gabbay YB, da Silva VB, Mascarenhas JD, Noronha VL, Clemens R, et al. Safety, immunogenicity, and protective efficacy of two doses of RIX4414 live attenuated human rotavirus vaccine in healthy infants. J Pediatr (Rio J) 2007; 83:217-24; PMID:17380232; http://dx.doi.org/10.2223/ JPED.1600 (Pubitemid 46883821)
14. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989; 8:431-40; PMID:2727467; http://dx.doi. org/10.1002/sim.4780080407 (Pubitemid 19105891)
15. De Vos B, Han HH, Bouckenooghe A, Debrus S, Gillard P, Ward R, Cheuvart B. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials. Pediatr Infect Dis J 2009; 28:261-6; PMID:19289978; http://dx.doi.org/10.1097/INF. 0b013e3181907177
16. Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 2001; 20:63-75; PMID:11176570; http://dx.doi. org/10.1097/00006454-200101000-00013 (Pubitemid 32066180)
17. Madhi SA, Cunliffe NA, Steele D, Witte D, Kirsten M, Louw C, Ngwira B, Victor JC, Gillard PH, Cheuvart BB, et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010; 362:289-98; PMID:20107214; http://dx.doi. org/10.1056/NEJMoa0904797
18. Zeng SQ, Halkosalo A, Salminen M, Szakal ED, Karvonen A, Vesikari T. Norovirus gastroenteritis in young children receiving human rotavirus vaccine. Scand J Infect Dis 2010; 42:540-4; PMID:20524782; http://dx.doi.org/10.3109/ 00365541003652556
19. Linhares AC, Verstraeten T, Wolleswinkel-van den Bosch J, Clemens R, Breuer T. Rotavirus serotype G9 is associated with more-severe disease in Latin America. Clin Infect Dis 2006; 43:312-4; PMID:16804845; http://dx.doi.org/10. 1086/505493 (Pubitemid 44078902)
20. Tregnaghi MW, Abate HJ, Valencia A, Lopez P, Da Silveira TR, Rivera L, Rivera Medina DM, Saez-Llorens X, Gonzalez Ayala SE, De León T, et al.; Rota-024 Study Group. Human rotavirus vaccine is highly efficacious when coadministered with routine expanded program of immunization vaccines including oral poliovirus vaccine in Latin America. Pediatr Infect Dis J 2011; 30:e103-8; PMID:21378594
21. Phua KB, Lim FS, Lau YL, Nelson EA, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009; 27:5936-41; PMID:19679216; http://dx.doi. org/10.1016/j.vaccine.2009.07.098
22. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Thollot F, Garcia-Corbeira P, Damaso S, Han HH, Bouckenooghe A. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010; 28:5272-9; PMID:20538094; http://dx.doi. org/10.1016/j.vaccine.2010.05.057
23. Kawamura N, Tokoeda Y, Oshima M, Okahata H, Tsutsumi H, Van Doorn LJ, Muto H, Smolenov I, Suryakiran PV, Han HH. Efficacy, safety and immunogenicity of RIX4414 in Japanese infants during the first two years of life. Vaccine 2011; 29:6335-41; PMID:21640780; http://dx.doi.org/10.1016/j. vaccine.2011.05.017
24. Vesikari T, Karvonen A, Puustinen L, Zeng SQ, Szakal ED, Delem A, De Vos B. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004; 23:937-43; PMID:15602194; http://dx.doi.org/10.1097/01. inf.0000141722.10130.50 (Pubitemid 40812781)
25. Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J 2005; 24:807-16; PMID:16148848; http://dx.doi.org/10.1097/01. inf.0000178294.13954.a1 (Pubitemid 41324890)
26. Phua KB, Emmanuel SC, Goh P, Quak SH, Lee BW, Han HH, Ward RL, Bernstein DI, De Vos B, Bock HL. A rotavirus vaccine for infants: the Asian experience. Ann Acad Med Singapore 2006; 35:38-44; PMID:16470273
27. Vesikari T, Karvonen A, Prymula R, Schuster V, Tejedor JC, Cohen R, Meurice F, Han HH, Damaso S, Bouckenooghe A. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007; 370:1757-63; PMID:18037080; http://dx.doi.org/10.1016/ S0140-6736(07)61744-9 (Pubitemid 350137490)
28. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990; 22:259-67; PMID:2371542; http://dx.doi. org/10.3109/00365549009027046
29. Gilchrist MJ, Bretl TS, Moultney K, Knowlton DR, Ward RL. Comparison of seven kits for detection of rotavirus in fecal specimens with a sensitive, specific enzyme immunoassay. Diagn Microbiol Infect Dis 1987; 8:221-8; PMID:2835201; http://dx.doi. org/10.1016/0732-8893(87)90053-8 (Pubitemid 18085827)
30. Ward RL, Bernstein DI, Young EC, Sherwood JR, Knowlton DR, Schiff GM. Human rotavirus studies in volunteers: determination of infectious dose and serological response to infection. J Infect Dis 1986; 154:871-80; PMID:3021869; http://dx.doi. org/10.1093/infdis/154.5.871 (Pubitemid 17181614)
31. Ward RL, Bernstein DI, Shukla R, Young EC, Sherwood JR, McNeal MM, Walker MC, Schiff GM. Effects of antibody to rotavirus on protection of adults challenged with a human rotavirus. J Infect Dis 1989; 159:79-88; PMID:2535868; http://dx.doi. org/10.1093/infdis/159.1.79 (Pubitemid 19021998)
32. Lin DY, Fleming TR, De Gruttola V. Estimating the proportion of treatment effect explained by a surrogate marker. Stat Med 1997; 16:1515-27; PMID:9249922; http://dx.doi.org/10.1002/(SICI)1097-0258(19970715)16:13<1515: :AIDSIM572> 3.0.CO;2-1 (Pubitemid 27322655)
33. Tang ML, Ng HK. Comment on: confidence limits for the ratio of two rates based on likelihood scores: non-iterative method. Stat Med 2004; 23:685-90, author reply 891-2; PMID:14755397; http://dx.doi. org/10.1002/sim.1683
34. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985; 41:55-68; PMID:4005387; http:// dx.doi.org/10.2307/2530643